

# Review of Patient Decision Aids for Psoriasis

PCR211



A. López Ferrer<sup>1</sup>, I. Belinchón<sup>2</sup>, M. Comellas Serra<sup>3</sup>, M. Garrido Clua<sup>3</sup>, A. Romero Maté<sup>4</sup>, B. Pérez Suárez<sup>5</sup>, S. Santos Alarcón<sup>6</sup> And P. De La Cueva<sup>7</sup>

1. Hospital Santa Creu i Sant Pau, Barcelona, Spain; 2. Dermatology Department, Dr. Balmis General University Hospital; Department of Clinical Medicine, Miguel Hernández University; ISABIAL, Alicante, Spain; 3. Outcomes'10 (A Productlife Group Company), Castellón de la Plana, Spain; 4. Hospital Universitario de Fuenlabrada, Madrid, Spain; 5. Hospital Morales Meseguer, Murcia, Spain; 6. Hospital Universitario Doctor Peset, Valencia, Spain; 7. Hospital Universitario Infanta Leonor, Madrid, Spain

## Introduction

Psoriasis (Pso) is a chronic, immune-mediated skin disease with a significant impact on patients' physical and psychological well-being<sup>1</sup>. Patient decision aids (PDAs) play a critical role in supporting shared decision-making by helping patients understand their options and incorporate their preferences into care decisions, ultimately improving treatment adherence and satisfaction<sup>2</sup>.

## Objective

To systematically identify and analyze existing PDAs developed for patients with psoriasis.

## Method

A defined search strategy to identify literature on decision aids for psoriasis through structured searches in PubMed and grey literature sources, including institutional websites<sup>3</sup> and non-indexed publications.

Data extraction: country of origin, format, target population, scope of treatment comparisons, inclusion of PDA core elements, and usability testing.

A PDA meets the criteria when it presents evidence-based information, supports reflection on patient values, and facilitates shared decision-making.

## Results

From 117 initial records, 6 tools met the inclusion criteria.

### COUNTRIES




Figure 1. Origin of Identified PDAs

### TARGET POPULATION




Figure 2. Target population of Identified PDAs

PDA characteristics	Number of identified (n,%)
Fulfilled PDA criteria	3 (50)
Usability testing performed	3 (50)
Treatment comparisons	
Broad categories (biologics vs. conventional therapies)	2 (33)
Specific drugs and modes of administration	4 (66)
Preference Section Included in PDA	3 (50)
Visual aids included in PDA	2 (33)
PDA Format	
Exclusively web-based	3 (50)
Paper and digital	3 (50)

Table 1. Characteristics of Identified PDAs

## Conclusion

No validated PDA currently exists for Spanish-speaking psoriasis patients.

This highlights a significant unmet need for the development of a culturally adapted, accessible, and patient-centered decision aid to support informed and shared decision-making among Spanish-speaking patients.

## REFERENCES

1. Bhosle, M.J., Kulkarni, A., Feldman, S.R. et al. Quality of life in patients with psoriasis. *Health Qual Life Outcomes* 2006;4:35. doi:10.1186/1477-7525-4-35.
2. Elwyn G, Frosch D, Thomson R, et al. Shared decision making: a model for clinical practice. *J Gen Intern Med*. 2012;27(10):1361–1367.
3. <https://decisionaid.ohri.ca>

CONTACT  
Marta Comellas Serra



[mcomellaserra@productlife-group.com](mailto:mcomellaserra@productlife-group.com)



OUTCOMES<sup>10</sup>  
A PRODUCTLIFEGROUP COMPANY

PLG  
ProductLifeGroup